MAURI MARIO

Pubblicazioni

  • Magistroni, V., Mauri, M., D'Aliberti, D., Mezzatesta, C., Crespiatico, I., Nava, M., et al. (2019). De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. HAEMATOLOGICA. Dettaglio
  • Piazza, R., Magistroni, V., Redaelli, S., Mauri, M., Massimino, L., Sessa, A., et al. (2018). SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. NATURE COMMUNICATIONS, 9(1), 2192. Dettaglio
  • Fontana, D., Mauri, M., Niro, A., Massimino, L., Bertagna, M., Zambrotta, G., et al. (2018). ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity. In Proceedings: AACR Annual Meeting 2018. Dettaglio
  • Fontana, D., Mauri, M., Niro, A., Massimino, L., Bertagna, M., Zambrotta, G., et al. (2018). ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION. Intervento presentato a: XV Congress of the Italian Society of Experimental Hematology, Rimini, Italy. Dettaglio
  • Redaelli, S., Ceccon, M., Zappa, M., Sharma, G., Mastini, C., Mauri, M., et al. (2018). Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. CANCER RESEARCH, 78(24), 6866-6880. Dettaglio